All Posts Tagged With: "PFE"

(BPL) A Safer Way to Higher Yields

Everyone wants yield today, and it’s getting harder and harder to find. As stock prices have risen, dividend yields have fallen. And not just for stocks but for many high-yield bonds as well. Over the past two years, dividend stocks have climbed in line with the S&P 500, both up 43%,...

4Feb2014 | | Comments Off | Continued

(PFE) Pfizer Halts Inotuzumab Study

Pfizer Inc. (PFE) recently faced a pipeline setback with the company discontinuing a late-stage study being conducted with its oncology candidate, inotuzumab ozogamicin. The randomized, open-label, two-arm phase III study was...

17Sep2013 | | Comments Off | Continued

(XNPT) XenoPort Candidate Disappoints

XenoPort, Inc. (XNPT) recently reported disappointing results on arbaclofen placarbil (AP) from a pivotal late-stage study (n=228). Results from the phase III trial showed that AP failed to achieve statistically significant...

7Aug2013 | | Comments Off | Continued

(NVS) Positive Data on Novartis’ Afinitor

Novartis (NVS) recently announced positive results on Afinitor, from a phase III trial, BOLERO-3. The study is evaluating Novartis’ Afinitor plus Roche’s (RHHBY)...

23Jul2013 | | Comments Off | Continued

(TEVA) Thoughts from Israel

Israel is a difficult place to live. As it is surrounded by its enemies, military service is compulsory for men and women. The men remain in the reserves, including yearly call-ups until age 40. Taxes are high and so is the cost of living. And other than a recently discovered natural gas field,...

16May2013 | | Comments Off | Continued

(ALKS) Pipeline Progress at Alkermes

Alkermes (ALKS) recently announced encouraging top-line data from a phase II study (n=142) on ALKS 5461. The study evaluated the safety and efficacy of ALKS 5461 across two doses for the treatment of major depressive disorder (MDD)...

2May2013 | | Comments Off | Continued

(PFE) Grading the First Quarter Earnings Season – Earnings Preview

Grading the Q1 Earnings Season We have crossed the halfway mark in the Q1 earnings season, with results from 271 S&P 500 companies already out (as of Friday, April 26th). Please note that these 271 companies are more than just 54.2% of the index’s total membership –...

2May2013 | | Comments Off | Continued

(ARIA) Ariad Pharmaceuticals Presents Data on AP26113

Ariad Pharmaceuticals, Inc. (ARIA) recently presented pre-clinical data on AP26113. The data presented by the company revealed that AP26113 can inhibit clinically relevant anaplastic lymphoba kinase (ALK) mutants resistant to Pfizer...

21Apr2013 | | Comments Off | Continued

(COV) Covidien plc Rolls Out More Concerta Drugs

Mallinckrodt, the Pharmaceuticals business of Covidien plc (COV), launched more dosages of the Concerta (methylphenidate HCl) Extended-Release (ER) Tablets USP (CII). The company introduced the new 36 mg and 54 mg dosage strengths. In...

11Apr2013 | | Comments Off | Continued

(MRK) Pharma & Biotech Stock Outlook – Apr 2013 – Zacks Analyst Interviews

The pharmaceutical industry has been showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s (PFE)...

7Apr2013 | | Comments Off | Continued

(NVS) Novartis Drug Candidate Earns Good News

Novartis (NVS) recently announced that the US Food and Drug Administration (FDA) rendered Breakthrough Therapy designation to its pipeline candidate LDK378. The Breakthrough Therapy designation includes all the features involved...

4Apr2013 | | Comments Off | Continued

(AZN) AstraZeneca to Revamp Research and Development Structure

AstraZeneca (AZN) recently announced that it plans to initiate strategic reforms in its research and development (R&D) segment. As per proposed plans, the company’s R&D activities will be primarily centered in three facilities...

1Apr2013 | | Comments Off | Continued

(JNJ) MedTech Industry Stock Outlook – January 2013 – Zacks Analyst Interviews

We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide medical devices market. The US still holds the leading position with almost one-third of the market share. However, emerging economies like Brazil, Russia, India and China –...

31Jan2013 | | Comments Off | Continued

(AZN) Management Expands at AstraZeneca

AstraZeneca (AZN) recently announced that the company has created seven positions in the senior executive team. At the same time, two senior roles were discontinued. We note that three of the seven newly created positions are...

22Jan2013 | | Comments Off | Continued

(ARQL) ArQule Shares Fall on Oncology Drug Candidate Setback

ArQule Inc. (ARQL) and partner Daiichi Sankyo recently announced disappointing phase II results on oncology candidate, tivantinib (ARQ 197). The study evaluated ArQule’s lead pipeline candidate, tivantinib, in combination with...

16Jan2013 | | Comments Off | Continued

(MDVN) Ignore the Smartest Guys in the Room – All 8,600 of Them

Everyone loves the long ball. Home runs are exciting. Sammy Sosa and Mark McGwire’s steroid-fueled race in 1998 brought baseball back from the damage caused by the players’ strike a few years earlier. Tony Gwynn’s hitting singles and doubles en route to a .368 batting average in...

15Jan2013 | | 0 comments | Continued

(COV) Covidien Drug Wins U.S. Food and Drug Administration Approval

Mallinckrodt, the Pharmaceuticals business of Covidien plc (COV), has won the U.S. Food and Drug Administration (FDA) approval to manufacture and sell a generic version of CONCERTA (methylphenidate HCl) Extended-Release (ER) Tablets...

3Jan2013 | | Comments Off | Continued

(EBS) Emergent BioSolutions Inks Deal with VaxInnate

Specialty pharmaceutical company, Emergent BioSolutions (EBS), recently signed a license agreement to gain an exclusive manufacturing right to VaxInnate Corporation’s pandemic influenza vaccine candidate in the U.S. Financial terms...

2Jan2013 | | Comments Off | Continued

(MRK) Merck Ties Up with GE Healthcare

Merck (MRK) is collaborating with GE Healthcare for the use of an investigational positron emission tomography (PET) imaging agent [18F (flutemetamol)] in the development of Merck’s Alzheimer’s disease candidate, MK-8931. Merck...

23Dec2012 | | Comments Off | Continued

(JNJ) Actelion Announces Positive Data on Drug Candidate

Actelion (ALIOF) recently announced positive results from a phase II study on its S1P1 modulator, ponesimod. Actelion is evaluating ponesimod as a treatment for patients suffering from moderate-to-severe chronic plaque psoriasis. The...

21Dec2012 | | Comments Off | Continued

(AZN) AstraZeneca Gets Positive News From Court

AstraZeneca (AZN) recently received some positive news when the Court of Appeals for the Federal Circuit maintained an earlier ruling that the US substance patent (RE37, 314) related to Crestor (rosuvastatin calcium) is valid. The...

20Dec2012 | | Comments Off | Continued

(WPI) An End to Drug Patent Woes?

The US Supreme Court will soon hear a case which will determine whether “pay-for-delay” agreements between drug manufacturers violate anti-trust legislations. These “reverse payment” agreements enable patent holders to pay generic drug manufacturers to delay the launch of generic versions...

16Dec2012 | | Comments Off | Continued

(AZN) AstraZeneca’s RA Drug Disappoints

AstraZeneca (AZN) and its partner Rigel Pharmaceuticals (RIGL) recently announced top-line data from the phase IIb OSKIRA-4 study evaluating the use of oral fostamatinib...

14Dec2012 | | Comments Off | Continued

(MRK) Merck’s Alzheimer’s Drug Progresses

Merck (MRK) recently moved its Alzheimer’s disease candidate, MK-8931, into a phase II/III study (EPOCH). The study will evaluate the safety and efficacy of MK-8931, an oral ?-amyloid precursor protein site-cleaving enzyme (BACE)...

11Dec2012 | | Comments Off | Continued

(MRK) Pharmaceuticals and Biotech Stock Outlook – December 2012 – Industry Outlook

The pharmaceutical industry is slowly showing signs of recovery from one of the biggest patent cliffs in recent times. The last few quarters saw major blockbusters like Merck’s (MRK) Singulair, Pfizer’s...

7Dec2012 | | Comments Off | Continued

(API) Stock Market News for October 17, 2012 – Market News

Better-than expected quarterly results combined with a couple of positive domestic reports guided the benchmarks into the green yesterday. Encouraging quarterly results buoyed hopes about a favorable third-quarter earnings season. The bullish sentiment helped the Dow post its biggest gain since September...

28Oct2012 | | Comments Off | Continued

(WMT) Stock Market News for October 16, 2012 – Market News

Strong September retail sales data coupled with better-than-expected quarterly results by Citigroup drove the benchmarks into the positive territory yesterday. The positive tone helped benchmarks to rebound from its previous week’s losses and guided Dow to register its biggest gain in one month....

16Oct2012 | | Comments Off | Continued

(GSK) GlaxoSmithKline Gets Encouraging Data on Cancer Drug

GlaxoSmithKline (GSK) recently presented positive data on its oncology drug, Votrient (pazopanib) from a pivotal phase III study. The phase III study COMPARZ (COMParing the efficacy, sAfety and toleRability of paZopanib vs. sunitinib)...

16Oct2012 | | Comments Off | Continued

(TEVA) Teva Pharmaceutical Industries Acquires Huntington Candidate

Teva Pharmaceutical Industries Ltd (TEVA) recently announced a deal that will expand the company’s central nervous system (CNS) pipeline. Teva acquired all rights, assets and obligations relating to Huntexil (pridopidine / ACR16)...

10Oct2012 | | Comments Off | Continued

(RDY) Generic Launch at Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories (RDY) recently announced the launch of its generic version of Merck & Co’s (MRK) Singulair oral granules (montelukast) following the...

9Oct2012 | | Comments Off | Continued